Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report
Open Access
- 14 April 2015
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (6) , 2567-2571
Abstract
Extraskeletal osteosarcomas (EOSs) are rare variants of primary osteosarcoma of the bone, and are defined as sarcomas located in the soft tissues and characterized by osteoid production. EOS exhibits distinctive demographic, imaging and prognostic features compared with osteosarcoma of bone origin. The available data are contradictory with regard to the use of chemotherapy regimens in the management of EOS. The present study describes a case of EOS that progressed following two lines of therapy oriented to soft-tissue and bone sarcoma histology, respectively. As a gemcitabine-docetaxel combination schedule has demonstrated synergistic activity against bone and soft-tissue sarcoma histologies, this chemotherapy regimen was selected as salvage therapy. The treatment was well-tolerated and induced a long lasting partial response for ~14 months. To the best of our knowledge, this is the first report involving the clinical use of this combination regimen for the treatment of EOS. Furthermore, as demonstrated in this report, EOS may maintain relative chemosensitivity, indicating the potential to control advanced disease in the long term and to plan subsequent chemotherapy regimens.Keywords
This publication has 26 references indexed in Scilit:
- Randomized Multicenter and Stratified Phase II Study of Gemcitabine Alone Versus Gemcitabine and Docetaxel in Patients with Metastatic or Relapsed Leiomyosarcomas: A Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)The Oncologist, 2012
- Efficacy and Safety of Gemcitabine-Docetaxel Combination Therapy for Recurrent or Refractory High-grade Osteosarcoma in China: A Retrospective Study of 18 PatientsJapanese Journal of Clinical Oncology, 2012
- Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003The Oncologist, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcomaCancer, 2008
- Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002Journal of Clinical Oncology, 2007
- Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysisInternational Journal of Cancer, 2006
- Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcomaJournal of Cancer Research and Clinical Oncology, 2005
- Extraskeletal Osteosarcoma: Analysis of Outcome of a Rare NeoplasmSarcoma, 2000
- Extraskeletal osteosarcoma. A clinicopathologic review of 26 casesCancer, 1990